Separate and combined effects of methylphenidate and a behavioral intervention on disruptive behavior in children with mental retardation.

Three children with severe intellectual disability took part. Each child had long bouts of screaming, hitting, and throwing things during class tasks.

The team used an alternating-treatments design. On different days the child got either methylphenidate, a behavioral plan, both, or nothing. The behavioral plan was simple: praise and small toys for staying on task, plus gentle hand-over-hand help called guided compliance.

Sessions were taped and scored by observers who did not know which condition was running that day.

The behavioral plan alone cut disruptive behavior to near zero for all three children. It also pushed their task engagement above eighty percent.

Methylphenidate worked well for two children, but added no extra benefit when paired with the behavioral plan. For the third child, the drug made little difference.

In short, behavior alone did the job; the pill was optional at best.

Pickering et al. (1985) saw the same pattern years earlier. They pitted contingency management against dextroamphetamine and thioridazine. Behavior won again; drugs gave shaky results.

Mace et al. (2009) extends the story. Even when stimulant medication helps, it never wipes out problem behavior fully. You still need a function-based plan.

Matson et al. (2011) looks like a contradiction. Their review says risperidone beats placebo for kids with ID. The key difference is design: L pooled large RCTs that lacked strong behavioral baselines. Cameron et al. (1996) used tight single-case controls, so behavior effects showed up faster and cleaner.

You can start with behavior first. Write a quick functional assessment, pick strong reinforcers, and teach guided compliance. If the team later wants a stimulant trial, you already have data to show whether the pill adds value. This saves time, side effects, and pharmacy costs.